Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $8.00 in the last session, down -6.98% from day before closing price of $8.60. In other words, the price has decreased by -$6.98 from its previous closing price. On the day, 2.6 million shares were traded. ARQT stock price reached its highest trading level at $9.0735 during the session, while it also had its lowest trading level at $7.97.
Ratios:
We take a closer look at ARQT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.80 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 2.32 whereas as Long-Term Debt/Eq ratio is at 2.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 02 ’24 when Watanabe Todd Franklin sold 13,783 shares for $8.74 per share. The transaction valued at 120,433 led to the insider holds 860,750 shares of the business.
Burnett Patrick sold 9,555 shares of ARQT for $83,490 on May 02 ’24. The insider now owns 259,745 shares after completing the transaction at $8.74 per share. On May 02 ’24, another insider, Matsuda Masaru, who serves as The insider of the company, sold 5,016 shares for $8.74 each. As a result, the insider received 43,829 and left with 185,408 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 924200000 and an Enterprise Value of 708561920. Its current Enterprise Value per Revenue stands at 11.887 whereas that against EBITDA is -2.958.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.18, which has changed by -0.39691442 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $15.21, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -20.74%, while the 200-Day Moving Average is calculated to be 23.66%.
Shares Statistics:
According to the various share statistics, ARQT traded on average about 3.87M shares per day over the past 3-months and 2216880 shares per day over the past 10 days. A total of 114.97M shares are outstanding, with a floating share count of 97.27M. Insiders hold about 15.40% of the company’s shares, while institutions hold 84.65% stake in the company. Shares short for ARQT as of 1713139200 were 19662102 with a Short Ratio of 5.08, compared to 1710460800 on 14992514. Therefore, it implies a Short% of Shares Outstanding of 19662102 and a Short% of Float of 20.629998999999998.
Earnings Estimates
The dynamic stock of Arcutis Biotherapeutics Inc (ARQT) is currently attracting attention from 5.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$0.73 for the current quarter, with a high estimate of -$0.6 and a low estimate of -$0.91, while EPS last year was -$1.31. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.55 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$1.9 and -$3.14 for the fiscal current year, implying an average EPS of -$2.42. EPS for the following year is -$1.33, with 6.0 analysts recommending between -$1.07 and -$1.88.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $14.74M. It ranges from a high estimate of $17M to a low estimate of $13.2M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $2.78MFor the next quarter, 5 analysts are estimating revenue of $24.04M. There is a high estimate of $28M for the next quarter, whereas the lowest estimate is $19.2M.
A total of 6 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $140M, while the lowest revenue estimate was $96.3M, resulting in an average revenue estimate of $116.1M. In the same quarter a year ago, actual revenue was $59.61MBased on 6 analysts’ estimates, the company’s revenue will be $229.8M in the next fiscal year. The high estimate is $260M and the low estimate is $185.7M.
